SK Biopharmaceuticals Co Ltd
KRX:326030

Watchlist Manager
SK Biopharmaceuticals Co Ltd Logo
SK Biopharmaceuticals Co Ltd
KRX:326030
Watchlist
Price: 120 400 KRW 0.67% Market Closed
Market Cap: 9.4T KRW

Net Margin

47.4%
Current
Improving
by 45.3%
vs 3-y average of 2.2%

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
47.4%
=
Net Income
₩320.5B
/
Revenue
₩675.4B

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
47.4%
=
Net Income
₩320.5B
/
Revenue
₩675.4B

Peer Comparison

Country Company Market Cap Net
Margin
KR
SK Biopharmaceuticals Co Ltd
KRX:326030
9.4T KRW
Loading...
US
Eli Lilly and Co
NYSE:LLY
982.2B USD
Loading...
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP
Loading...
US
Johnson & Johnson
NYSE:JNJ
526.1B USD
Loading...
CH
Roche Holding AG
SIX:ROG
277.8B CHF
Loading...
UK
AstraZeneca PLC
LSE:AZN
217.9B GBP
Loading...
CH
Novartis AG
SIX:NOVN
221.8B CHF
Loading...
US
Merck & Co Inc
NYSE:MRK
270.7B USD
Loading...
DK
Novo Nordisk A/S
CSE:NOVO B
1.7T DKK
Loading...
IE
Endo International PLC
LSE:0Y5F
213.9B USD
Loading...
US
Pfizer Inc
NYSE:PFE
145.8B USD
Loading...
No Stocks Found

Market Distribution

Higher than 98% of companies in Korea
Percentile
98th
Based on 1 530 companies
98th percentile
47.4%
Low
-168 471.3% — -1.3%
Typical Range
-1.3% — 6.7%
High
6.7% — 21 012.5%
Distribution Statistics
Korea
Min -168 471.3%
30th Percentile -1.3%
Median 2.4%
70th Percentile 6.7%
Max 21 012.5%

SK Biopharmaceuticals Co Ltd
Glance View

Market Cap
9.4T KRW
Industry
Pharmaceuticals

SK Biopharmaceuticals Co., Ltd., a prominent player in the global biopharmaceutical industry, emerged as a distinctive entity out of one of South Korea's largest conglomerates, the SK Group. This pharmaceutical jewel draws its strength from innovation in the neurology and oncology sectors, fields brimming with both challenge and opportunity. At its core, SK Biopharmaceuticals is dedicated to the research, development, and commercialization of novel medications, with a significant focus on disorders impacting the central nervous system. Their pipeline and commercial activities revolve around cutting-edge therapies, such as the epilepsy drug Cenobamate, which has gained a foothold in both the U.S. and European markets. This drug, marketed under different names like Xcopri in the U.S., is a testament to the company's ability to leverage robust R&D capabilities into profitable products. Revenue generation for SK Biopharmaceuticals is predominantly driven by the sales of their innovative therapeutic solutions, as well as strategic collaborations with a network of global partners. They engage in a lifecycle approach where they not only develop and launch their own drugs but also license out their intellectual property, enhancing revenue streams through royalties and milestone payments. This hybrid model of sales and strategic partnerships showcases a deft mix of scientific prowess and commercial acumen, key to sustaining and propelling growth in a competitive market. Additionally, they continuously invest in research and alliances, aiming to expand their portfolio beyond existing successes, while targeting unmet medical needs that mirror their core strengths. This balanced approach positions SK Biopharmaceuticals not just as a standalone drugmaker, but as a dynamic player in shaping future therapies in their chosen niches.

Intrinsic Value
83 154.4 KRW
Overvaluation 31%
Intrinsic Value
Price
What is Net Margin?
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
How is Net Margin calculated?

Net Margin is calculated by dividing the Net Income by the Revenue.

Net Margin
47.4%
=
Net Income
₩320.5B
/
Revenue
₩675.4B
What is SK Biopharmaceuticals Co Ltd's current Net Margin?

The current Net Margin for SK Biopharmaceuticals Co Ltd is 47.4%, which is above its 3-year median of 2.2%.

How has Net Margin changed over time?

Over the last 3 years, SK Biopharmaceuticals Co Ltd’s Net Margin has increased from -11.7% to 47.4%. During this period, it reached a low of -56.6% on Dec 31, 2022 and a high of 47.4% on Oct 30, 2025.

Back to Top